Publications

Zanidatamab
Lancet Oncology
June 2, 2023
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Harding et al.
Preclinical
Bioorganic & Medicinal Chemistry Letters
June 2, 2023
Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates
Brant et al.
Preclinical
PEGS
May 15 - May 19, 2023
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
ZW171
PEGS
May 19, 2023
Engineering and Preclinical Development of ZW171: A 2+1 Format Anti-MSLN T Cell Engager
Piscitelli et al.
Preclinical
PEGS
May 15 - May 19, 2023
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Bhojane et al.